Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Apolo, A
Baumann, BC
Al-Ahmadie, H
Ballas, L
Bangs, R
Brothers, K
Greenberg, SC
Delacroix, S
Dignam, JJ
Efstathiou, JA
Feldman, AS
Foster, JC
Hahn, NM
Hall, E
Hansel, DE
Hoffman-Censits, J
Kamat, AM
Kamran, SC
Khani, F
Lerner, SP
Lipman, R
Mann, B
McConkey, D
McKiernan, J
Rose, TL
Smith, AB
Tangen, C
Amiri, AT
Weinstock, C
West, PJ
Milowsky, MI
Black, PC
Baumann, BC
Al-Ahmadie, H
Ballas, L
Bangs, R
Brothers, K
Greenberg, SC
Delacroix, S
Dignam, JJ
Efstathiou, JA
Feldman, AS
Foster, JC
Hahn, NM
Hall, E
Hansel, DE
Hoffman-Censits, J
Kamat, AM
Kamran, SC
Khani, F
Lerner, SP
Lipman, R
Mann, B
McConkey, D
McKiernan, J
Rose, TL
Smith, AB
Tangen, C
Amiri, AT
Weinstock, C
West, PJ
Milowsky, MI
Black, PC
Document Type
Journal Article
Date
2025-01-01
Date Accepted
2025-01-18
Abstract
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cancer Task Force of the NCI Genitourinary Cancers Steering Committee. The purpose of this meeting was to accelerate advances in clinical trials for patients with high-risk NMIBC. The meeting delivered a multidisciplinary expert consensus on optimal strategies for next-generation clinical trial designs in NMIBC with prioritization of combination therapies. Two clinical trial concepts were developed for potential implementation within the National Clinical Trials Network.
Citation
Bladder Cancer, 2025, 11 (1), pp. 23523735251319185 -
Source Title
Bladder Cancer
Publisher
SAGE PUBLICATIONS INC
ISSN
2352-3727
eISSN
2352-3735
Collections
Research Team
Clin Trials & Stats Unit